Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go?

Lim C.-K.Wei Y.-F.Tsai M.-S.KUAN-YU CHENJIN-YUAN SHIHCHONG-JEN YU2022-06-272022-06-2720180959-8049https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052997624&doi=10.1016%2fj.ejca.2018.07.128&partnerID=40&md5=284a0237402b7b4b8440e901bfd61defhttps://scholars.lib.ntu.edu.tw/handle/123456789/614068Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go?journal article10.1016/j.ejca.2018.07.128301997682-s2.0-85052997624